Bezlotoxumab (Zinplava) for prevention of recurrent Clostridium difficile infection

JAMA - Journal of the American Medical Association

Volumn 318, Issue 7, 2017, Pages 659-660

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BEZLOTOXUMAB;

CLOSTRIDIUM DIFFICILE INFECTION; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FECAL MICROBIOTA TRANSPLANTATION; FEVER; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOGENICITY; INFUSION RELATED REACTION; NAUSEA; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 85027884550     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.10092     Document Type: Short Survey

References (11)

1. See I, Mu Y, Cohen J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis. 2014;58(10):1394-1400.
2. Gerding DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S32-S42.
3. Stevens VW, Nelson RE, Schwab-Daugherty EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med. 2017;177(4):546-553.
4. Fidaxomicin (Dificid) for Clostridium difficile infection. Med Lett Drugs Ther. 2011;53(1373):73-74.
5. Goldenberg SD, Brown S, Edwards L, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016;35(2):251-259.
6. Rao K, Safdar N. Fecal microbiota transplantation for the treatment of Clostridium difficile infection. J Hosp Med. 2016;11(1):56-61.
7. Hota SS, Sales V, Tomlinson G, et al. Oral vancomycin followed by fecal transplantation versus tapering oral vancomycin treatment for recurrent Clostridium difficile infection: an open-label, randomized, controlled trial. Clin Infect Dis. 2017;64(3):265-271.
8. Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83(2):822-831.
9. Wilcox MH, Gerding DN, Poxton IR, et al; MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376(4):305-317.
10. Prabhu V, et al. Bezlotoxumab decreases CDI recurrence and is associated with a reduction in 30-day readmissions: European analysis. Presented at: European Congress of Clinical Microbiology and Infectious Diseases; April 9-12, 2016; Amsterdam, the Netherlands. Abstract P1340.
11. First Databank Inc. Approximate wholesaler acquisition cost or manufacturer’s published price to wholesalers. http://www.fdbhealth.com/policies/drug-pricing-policy. Accessed July 17, 2017.